A Phase 3 interventional study of BHV-1300 and Placebo in Graves Disease, sponsored by Biohaven Therapeutics Ltd.. Recruiting at 63 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Biohaven Therapeutics Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Graves Disease with a site in United States — 16 open to participants now, 18 under way, 3 of them phase 3. Graves Disease · United States.
Among the 43 studies in Graves Disease with a site in United States, this one is the 2nd largest by planned enrollment of the 33 interventional ones that give a count, is one of 10 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 10 of the 17 other live ones, and was the 39th registered.
162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.
Browse Graves Disease studies →16 of the 43 studies in Graves Disease with a site in United States are open now. Recruiting first, the newest first:
Sling Therapeutics, Inc. · Sites in United States
Ages 18+
Biogen · Sites in United States, Puerto Rico
Ages 18–75
Appalachian State University · Sites in United States
Ages 18–65
Ethyreal Bio, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
argenx · Sites in United States, Georgia, United Kingdom
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Graves Disease studies recruiting now, 17 (44%) set no upper age limit and 20 (51%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 10 · Phase 4 4
First in 1993; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 60 across 104 interventional studies indexed under Graves Disease.
Median enrollment 76 across the 33 interventional studies, 42 across the 10 observational. Of the 21 that completed or were terminated, 11 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 43 have an industry lead sponsor. The 10 most frequent:
Biohaven Therapeutics Ltd. is the lead sponsor of 20 studies on the registry; 9 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Biohaven Therapeutics Ltd. has 3 studies filed under Graves Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Graves Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05435547Indiana UniversityPreoperative Corticosteroids in Autoimmune Thyroid Disease | 2026-12-30 |
| NCT07413874Appalachian State UniversityTelehealth Music Therapy for Adults With Endocrine Disorder and Depression | 2026-12-31 |
| NCT07018323Immunovant Sciences GmbHA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease | 2027-05 |
| NCT06980649Biohaven Therapeutics Ltd.Study of BHV-1300 in Graves' Disease | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies in Graves Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BHV-1300 is delivered subcutaneously via autoinjector. Participants will be randomized in a 2:1 ratio to receive either BHV-1300 or placebo.
Drug: BHV-1300
Matching placebo is delivered subcutaneously via autoinjector. Participants will be randomized in a 2:1 ratio to receive either BHV-1300 or placebo.
Drug: Placebo
delivered subcutaneously via autoinjector
delivered subcutaneously via autoinjector
Number of participants on BHV-1300 vs placebo who are not on an antithyroid drug and with normal thyroid function (total T3, free T4 (FT4), & TSH within normal limits) at Week 26.
Time frame: Week 26
Number of participants on BHV-1300 vs placebo who are not on an antithyroid drug and with normal thyroid hormone (Total T3 and FT4) at Week 26.
Time frame: Week 26
Change from baseline in TRAb (TBII) of participants on BHV-1300 vs placebo at Week 6
Time frame: Baseline to Week 6
Change from baseline in TRAb (TBII) of participants on BHV-1300 vs placebo at Week 26
Time frame: Baseline to Week 26
Exposure-adjusted Cumulative ATD dose, of participants on BHV-1300 vs placebo at Week 26
Time frame: Week 26
Time to normal thyroid hormones (defined as Total T3 & FT4 within normal limits) and off ATD of participants on BHV-1300 vs placebo
Time frame: Up to 26 weeks
Time to euthyroidism (defined as Total T3, FT4, and TSH within normal limits) and off ATD of participants on BHV-1300 vs placebo
Time frame: Up to 26 weeks
Change from baseline in Total IgG of participants on BHV-1300 vs placebo at Week 6
Time frame: Baseline to Week 6
Change from baseline in Total IgG of participants on BHV-1300 vs placebo at Week 26
Time frame: Baseline to Week 26
Number of participants who are TRAb seronegative (defined as TRAb < ULN) at Week 26
Time frame: Week 26
Number of participants who are euthyroid (defined as Total T3, FT4, and TSH within normal limits), off ATD and TRAb seronegative at Week 26
Time frame: Week 26
Number of unique participants with SAEs, moderate and severe AEs, AEs leading to discontinuation or deaths
Time frame: Up to 26 weeks
Number of unique participants with Grade 3 to 4 lab abnormalities
Time frame: Up to 26 weeks
Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BHV-1300
Biohaven Therapeutics Ltd.